In today’s recent session, 1.0 million shares of the Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) have been traded, and its beta is 1.44. Most recently the company’s share price was $6.84, and it changed around $0.11 or 1.56% from the last close, which brings the market valuation of the company to $977.38M. AUPH at last check was trading at a discount to its 52-week high of $10.24, offering almost -49.71% off that amount. The share price’s 52-week low was $4.71, which indicates that the recent value has risen by an impressive 31.14% since then. We note from Aurinia Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.57 million shares, with the 3-month average coming to 1.32 million.
Aurinia Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.43. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended AUPH as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Aurinia Pharmaceuticals Inc is expected to report earnings per share of 0.01 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) trade information
Instantly AUPH has been showing a green trend so far today with a performance of 1.56% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 6.95 on recent trading dayincreased the stock’s daily price by 1.58%. The company’s shares are currently down -23.97% year-to-date, but still up 3.72% over the last five days. On the other hand, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 21.62% up in the 30-day period. We can see from the shorts that 8.48 million shares have been sold at a short interest cover period of 5.72 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 43.0% from its current value. Analyst projections state that AUPH is forecast to be at a low of $6 and a high of $26.
Aurinia Pharmaceuticals Inc (AUPH) estimates and forecasts
Aurinia Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 17.04 percent over the past six months and at a 107.41% annual growth rate that is well above the industry average of 20.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 111.10% in revenue this quarter, and will report an increase of 147.40% in the next quarter. The year-over-year growth rate is expected to be 33.40%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 56.09M in revenue for the current quarter. 6 analysts expect Aurinia Pharmaceuticals Inc to make 69.97M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 54.52M and 45.09M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 2.90%. Forecasts for the next quarter put sales growth at 55.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.35%.
AUPH Dividends
Aurinia Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Oct-31.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 7.07% of Aurinia Pharmaceuticals Inc shares, and 40.54% of them are in the hands of institutional investors. The stock currently has a share float of 43.63%. Aurinia Pharmaceuticals Inc stock is held by 239.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 7.7326% of the shares, which is about 11.14 million shares worth $63.59 million.
BLACKROCK INC., with 6.4384% or 9.27 million shares worth $52.94 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Fidelity Small Cap Index Fund were the top two Mutual Funds as of May 31, 2024 . The former held 3.1 shares worth $21.03 million, making up 2.17% of all outstanding shares. On the other hand, Fidelity Small Cap Index Fund held roughly 1.35 shares worth around $9.15 million, which represents about 0.95% of the total shares outstanding.
